Virtual Panel Discussion - Redefining Cancer Treatment: Targeting Gene Fusions
sponsored by Invitae
December 2 2020, 4:30 - 5:30pm CET
ArcherDX , now Invitae is a leading genomics company democratizing precision oncology. We offer a suite of research products that are powered by our proprietary Anchored Multiplex PCR (AMP™) chemistry, including FusionPlex®, VariantPlex®, LiquidPlex™ and Immunoverse™. Additionally, we are developing IVD products for solid tumor biomarker identification and Personalized Cancer Monitoring (PCM™), but which are not yet approved for clinical or diagnostic use. For more information visit www.archerdx.com.
Gene rearrangements in cancers don't stop at ALK and ROS1. Taken individually, rearrangements in RET, NTRK, EGFR, BRAF, and FGFR are rare – but, taken together and paired with universal comprehensive molecular profiling, more actionable targets come to light. In this webinar, three experts will share their experiences and examine the data supporting the role of fusions in these genes as cancer drivers. They will also present case studies focusing on fusions from diagnosis to treatment. Finally, a roundtable Q&A session will give you the opportunity to get the information you need to satisfy your curiosity about these less commonly discussed gene rearrangements.
- Frederique Penault-Llorca, University of Clermont-Ferrand
- Nicola Normanno, Fondazione Pascale Naples
- Svenja Wagener. University of Cologne
For Research Use Only. Not for use in diagnostic procedures.